NOTCH pathway inactivation promotes bladder cancer progression

Journal of Clinical Investigation

Volumn 125, Issue 2, 2015, Pages 824-830

  Maraver, Antonio ^a,e   Fernandez Marcos, Pablo J ^a   Cash, Timothy P ^a   Mendez Pertuz, Marinela ^a   Dueñas, Marta ^b   Maietta, Paolo ^a   Martinelli, Paola ^a   Muñoz Martin, Maribel ^a   Martínez Fernández, Mónica ^b   Cañamero, Marta ^a   Roncador, Giovanna ^a   Martinez Torrecuadrada, Jorge L ^a   Grivas, Dimitrios ^c   De La Pompa, Jose Luis ^c   Valencia, Alfonso ^a   Paramio, Jesús M ^b   Real, Francisco X ^a,d   Serrano, Manuel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; TRANSCRIPTION FACTOR HES 1; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; HES1 PROTEIN, HUMAN; HES1 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; NOTCH1 PROTEIN, HUMAN; NOTCH1 PROTEIN, MOUSE; NOTCH2 PROTEIN, HUMAN; NOTCH2 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; ANIMAL; BLADDER TUMOR; CLINICAL TRIAL; FEMALE; GENETICS; MALE; METABOLISM; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; RECEPTOR, NOTCH1; RECEPTOR, NOTCH2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84961291516     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78185     Document Type: Article

References (51)

1. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet. 2012;13(9):654-666.
2. Ntziachristos P, Lim JS, Sage J, Aifantis I. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell. 2014;25(3):318-334.
3. Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271.
4. Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
5. Westhoff B, et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A. 2009;106(52):22293-22298.
6. Agrawal N, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154-1157.
7. Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157-1160.
8. Wang NJ, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011;108(43):17761-17766.
9. Klinakis A, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011;473(7346):230-233.
10. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Kleihues, P, Sobin, LH, eds. Lyon, France: IARCPress; 2004.
11. Scosyrev E, Yao J, Messing E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology. 2009;73(4):822-827.
12. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-322.
13. Balbas-Martinez C, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet. 2013;45(12):1464-1469.
14. Guo G, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013;45(12):1459-1463.
15. Cordle J, et al. A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nat Struct Mol Biol. 2008;15(8):849-857.
16. Hass MR, Sato C, Kopan R, Zhao G. Presenilin: RIP and beyond. Semin Cell Dev Biol. 2009;20(2):201-210.
17. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216-233.
18. Saura CA, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42(1):23-36.
19. Tanigaki K, et al. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol. 2002;3(5):443-450.
20. Puzio-Kuter AM, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23(6):675-680.
21. Mao X, Fujiwara Y, Orkin SH. Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci U S A. 1999;96(9):5037-5042.
22. Shin K, et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat Cell Biol. 2014;16(5):469-478.
23. Bryan GT. The pathogenesis of experimental bladder cancer. Cancer Res. 1977;37 (8 pt 2):2813-2816.
24. Garcia-Cao I, et al. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep. 2005;6(6):577-583.
25. Chu PG, Lyda MH, Weiss LM. Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours. Histopathology. 2001;39(1):9-16.
26. Espinosa L, et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell. 2010;18(3):268-281.
27. Maraver A, et al. Therapeutic effect of gamma-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell. 2012;22(2):222-234.
28. Palomero T, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-1210.
29. Wendorff AA, et al. Hes1 is a critical but contextdependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity. 2010;33(5):671-684.
30. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013;342(6159):1234850.
31. Real PJ, et al. γ-Secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15(1):50-58.
32. Santos M, et al. In vivo disruption of an Rb-E2FEzh2 signaling loop causes bladder cancer. Cancer Res. 2014;74(22):6565-6577.
33. Rhodes DR, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1-6.
34. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24(5):778-789.
35. Lee JS, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010;28(16):2660-2667.
36. Gao YB, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46(10):1097-1102.
37. Abdou AG, El-Wahed MM, Kandil MA, Samaka RM, Elkady N. Immunohistochemical analysis of the role and relationship between Notch-1 and Oct-4 expression in urinary bladder carcinoma. APMIS. 2013;121(10):982-996.
38. Li W, et al. High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Int J Clin Exp Pathol. 2013;6(11):2430-2440.
39. Hirao S, et al. Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer. 2005;104(9):1918-1923.
40. Shi TP, et al. Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. J Urol. 2008;180(1):361-366.
41. Rafnar T, et al. Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Hum Mol Genet. 2014;23(20):5545-5557.
42. Nickoloff BJ, Qin JZ, Chaturvedi V, Denning MF, Bonish B, Miele L. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-κB and PPARγ. Cell Death Differ. 2002;9(8):842-855.
43. Rangarajan A, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001;20(13):3427-3436.
44. Alcolea MP, Greulich P, Wabik A, Frede J, Simons BD, Jones PH. Differentiation imbalance in single oesophageal progenitor cells causes clonal immortalization and field change. Nat Cell Biol. 2014;16(6):615-622.
45. Espinoza I, Miele L. Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett. 2013;341(1):41-45.
46. Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia. 2009;23(8):1374-1377.
47. Maraver A, Serrano M. Notching up a new therapeutic strategy for non-small cell lung carcinoma (NSCLC). Oncotarget. 2012;3(9):917-918.
48. Plentz R, et al. Inhibition of γ-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 2009;136(5):1741-1749 e1746.
49. Van Es JH, et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959-963.
50. Schott AF, et al. Preclinical and clinical studies of γ secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013;19(6):1512-1524.
51. Hernandez S, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664-3671.